Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Abstract: The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.

Abstract: 3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.

Abstract: N-sulfamoyl-N?-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.

Abstract: The present invention relates to the use of known and novel N-sulfamoyl-N?-arylpiperazines corresponding to Formula I and their physiologically compatible acid addition salts for the treatment or inhibition of obesity and related conditions.

Abstract: Pharmacologically active compounds of the general formula I wherein R1 is an alkyl group with 1-6 carbon atoms or a cycloalkylalkyl group with 4-7 carbon atoms, R2 is lower alkyl, and R3 is lower alkyl, or R2 and R3 together form an alkylene chain with 3-6 carbon atoms, and R4 represents a phenyl radical monosubstituted in the ortho or para position by nitro, cyano or lower alkanoyl or disubstituted in the ortho and para positions by nitro, and their physiologically compatible acid addition salts are described.

Abstract: Pharmacologically active compounds of the general formula I 1

Abstract: The invention relates to an Ultrasound Sensor, especially for a vehicle and the passenger compartment thereof, comprising a can-shaped housing, a housing base, a housing closure and a sensor element arranged at the base inside the housing, and in the area of the housing closure there is arranged a contact device which is attachable, in locally fixed fashion, inside housing; the contact device presenting, in the direction of the longitudinal axis, a penetrating recess and being connected, in electrically conductive fashion, in at least one contact point with at least one electrode of the sensor element by means of thick-stranded wire. The invention also relates to a method for producing the Ultrasound Sensor.

Abstract: A fuse apparatus (1) is provided for selectively interrupting a load current (Ia) flowing between a pair of associated conductor leads. The fuse apparatus includes at least two spaced apart electrically conductive contact elements (5) operatively connected with the associated conductor leads. A fuse element (7) is connected to the contact elements (5) using an electrically conductive connection material (9) to allow the current (Ia) to flow between the pair of associated conductor leads. The connection material (9) is adapted to electrically disconnect the fuse element (7) from the contact elements (5) when the current (Ia) exceeds a predetermined current intensity. The connection material (9) has an intrinsic electrical transition resistance characteristic whereby the material develops a temperature in proportion to an intensity of the current. The connection material melts as the current increases to separate the fuse element from the contact elements.

Abstract: N-triazolylmethyl-piperazine compounds which exhibit neurokinin receptor antagonistic activity corresponding to the formula I: wherein R1, R2 and R3 have the meanings given in the specification; pharmaceutical compositions containing these compounds; a process for preparing these compounds, and intermediate products of this process.

Abstract: A process for preparing epoxysilanes by reacting a hydrogensilane with an allyl glycidyl ether in the presence of a catalyst and working up the crude product obtained, where the catalyst is removed from the crude product and the crude product is subsequently distilled.

Abstract: N-triazolylmethyl-piperazine compounds which exhibit neurokinin receptor antagonistic activity corresponding to the formula I: 1

Abstract: The invention relates to a process for preparing vinyl chlorosilanes, that includes thermally and non-catalytically reacting chlorosilane with vinyl chloride at a temperature of 550 to 700° C. by flowing the chlorosilane and vinyl chloride through a ring-gap space in a ring-gap reactor to produce a reaction gas; the ring-gap space having a cross-sectional area and a volume; and, after the flowing, further reacting, adiabatically, the reaction gas in a second zone to produce a hot reaction gas that contains vinylchiorosilane; wherein the second zone has a cross-sectional area that is greater than the cross-sectional area of the ring-gap space; and wherein the second zone has a volume that is in a ratio to the volume of the ring-gap space of 0.15:1 to 1.5:1. The invention also provides an apparatus for carrying out the above process.

Abstract: A process for the continuous preparation of 3-halopropylorganosilanes of the general structure RbH3-a-bXaSiCH2CH2CH2Y  (III), where: R is CH3, C2H5, C3H7, OCH3, OC2H5 or OC3H7, X is F, Cl, Br or I, Y is F, Cl, Br or I, and a and b are each one of the numbers 0, 1, 2 or 3 and the sum a+b is 1, 2 or 3, comprising reacting, as starting materials, an allyl halide with a silane carrying at least one H atom, wherein the starting materials are present in stoichiometric amounts or one of the starting materials is present in substoichiometric amounts, wherein the reaction carried out is a partial reaction of from 10% to 80%, on a molar basis, of the starting materials, based on either material, when both are present in stoichiometric amounts, or based on the substoichiometric material.

Abstract: The invention relates to a process for preparing vinylchlorosilanes by thermal non-catalyzed reaction of chlorosilanes with vinyl chloride at from 550 to 700° C., using a ring-gap reactor which includes rapidly cooling the hot reaction gases after they have flowed through the ring-gap space, by quenching them with a liquid.

Abstract: The invention relates to a process for preparing 3-glycidyloxypropyltrialkoxysilanes of the general formulaCH.sub.2 (O)CHCH.sub.2 --O--(CH.sub.2).sub.3 Si(OR).sub.3 (I),in which R is an alkyl radical, by reacting allyl glycidyl etherCH.sub.2 (O)CHCH.sub.2 --O--CH.sub.2 CH.dbd.CH.sub.2 (II),with a trialkoxysilane of the general formulaHSi(OR).sub.3 (III),in which R is again an alkyl radical, in a heterogeneous, platinum-catalyzed hydrosilylation reaction, where the catalyst employed is a platinum(0) catalyst on a nonmetallic support.

Abstract: Compounds having fibrinogen receptor-antagonistic activity, of the general formula I ##STR1## in which Z is oxygen or a methylene group,B is a phenyl or pyridyl radical,R.sup.1 is hydrogen or a group forming a biolabile ester, and their physiologically acceptable acid addition salts and physiologically acceptable salts of acids of formula I.

Abstract: The use of 3,7,9,9-tetrasubstituted 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds for treating cardiac arrhytmias in larger mammals, including humans; novel antiarrhythmically active 3,7,9,9-tetrasubstituted compounds corresponding to the general formula Ia ##STR1## in which R.sup.1 is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms,R.sup.2 is lower alkyl, andR.sup.3 is lower alkyl, orR.sup.2 and R.sup.3 together form an alkylene chain having 3-6 carbon atoms,R.sup.4' is cyano, an R.sup.6 --O--CO-- group in which R.sup.6 is lower alkyl, an R.sup.7 --SO.sub.2 --NH-- group in which R.sup.7 is lower alkyl, or an R.sup.8 --CO--NH-- group in which R.sup.8 is lower alkyl or a phenyl group which is optionally substituted by halogen, cyano, nitro, or an R.sup.9 --SO.sub.2 -- radical in which R.sup.9 is lower alkyl, or an imidazolyl radical located in position 4 of the phenyl ring, andR.sup.

Abstract: The use of 3,7,9,9-tetrasubstituted 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds for treating cardiac arrhythmias in larger mammals, including humans; novel antiarrhythmically active 3,7,9,9-tetrasubstituted compounds corresponding to the general formula Ia ##STR1## in which R.sup.1 is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms,R.sup.2 is lower alkyl, andR.sup.3 is lower alkyl, orR.sup.2 and R.sup.3 together form an alkylene chain having 3-6 carbon atoms,R.sup.4 ' is cyano, an R.sup.6 --O--CO-- group in which R.sup.6 is lower alkyl, an R.sup.7 --SO.sub.2 --NH-- group in which R.sup.7 is lower alkyl, or an R.sup.8 --CO--NH-- group in which R.sup.8 is lower alkyl or a phenyl group which is optionally substituted by halogen, cyano, nitro or an R.sup.9 --SO.sub.2 -- radical in which R.sup.9 is lower alkyl, or an imidazolyl radical located in position 4 of the phenyl ring, andR.sup.

Abstract: The use of 3-benzoyl-3,7-diazabicyclo[3.3.1]nonane compounds of the general formula I ##STR1## in which R.sup.1 is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms,R.sup.2 and R.sup.3 are each individually lower alkyl or together form an alkylene chain having 3-6 carbon atoms,R.sup.4 is hydrogen, halogen, cyano, nitro, trifluoromethyl or a R.sup.6 --SO.sub.2 -- group, in which R.sup.6 is fluorine or lower alkyl, andR.sup.5 is hydrogen, halogen, trifluoromethyl or nitro, or their physiologically acceptable acid addition salts for the treatment of cardiac arrhythmias in larger mammals, including humans.